while production of proprietary Chinese medicine Enterprise reduce the stock

Editor's Note: plates of traditional Chinese medicine 22.99% for the first three quarters of sales growth in revenue, higher than the overall 21.05% of the pharmaceutical sector growth. Current domestic listed companies typically have multiple base of traditional Chinese medicine drug or health insurance as well as exclusive species, niche concentration of relatively strong and established through the brand strength or means of protection of traditional Chinese medicine higher barriers in order to gainA long-term good development environment. At the same time due to the characteristics of traditional Chinese medicine, in the areas of cardiovascular medicine, anticancer drugs, Chinese medicine can give full play to its role in target, market size and prospects are very substantial.　　In addition, in the field of cosmetic and health products, some enterprises will face of inflection points of profit opportunities. Medicine prices rebound in corporate profits main capital stocks (Eleven-twenty fifths) unit fled to cut meat must regret having sudden boom is not likely in a move investors Gospel: hold stocks saved! By the medicinal plant resources of traditional Chinese medicine, medicinal mineral medicinal animals and three parts, about 11,118 species of medicinal plants, natural medicine raw material suppliers, mainly to China, India and Brazil. World Bank reports that 2000 natural drugs industry in the world around US $ 80 billion, 2010 up to $ 200 billion, international natural medicines market is expanding rapidly. The first half of 2011, domestic enterprises of proprietary Chinese medicines prevalent phenomenon of rising operating costs, pientzehuang, Guangzhou pharmaceutical, Kang margin, Jilin aodong medicine industry and sectors such as traditional Chinese medicine Jiang, operating costs increase revenue increase by more than 10%。 Beginning in July, relevant departments of the national drug stockpile increase the intensity of combat, while production of proprietary Chinese medicine Enterprise reduce the stock, coupled with the herbalist broadening the scope of planting, breeding, herbs this year a large number of listed factors prompted the Chinese medicinal material prices began to fall. As of October 2011, price the highest point by 13.55% Chengdu traditional Chinese medicines, Chinese herbal medicines prices continuouslyRose finally reversed the trend for many years, will enable enterprises of Chinese herbal medicines as the main raw material before heavy cost pressures have eased. For manufacturers of proprietary Chinese medicines, and grasp the quality from the source is the first priority of the protection of Chinese traditional medicine production. Proprietary Chinese medicine enterprises with upstream resource dependencies, building GAP base is the best way of achieving sustainable development of enterprise scaleOrganizations with higher levels of "contract farming" or widely promoted in the future. By the end of 2010, more than a total of more than 50 enterprises of Chinese medicinal materials in China, 72 base 52 species through the GAP of Chinese medicinal materials certification. Tasly by listed companies, such as tongrentang, 39 pharmaceutical companies are an earlier batch of Chinese medicinal material GAP began planning and planting of proprietary Chinese medicine production enterprisesIndustry. Profits continued to hold of proprietary Chinese medicines as well as proprietary Chinese medicines in September 2011, production was 220,300 tons, an increase of 51.32%, yields since 2007 and has been in the trend of escalation, 2011-September yield growth rates are higher than the 40% of traditional Chinese medicine, far above the growth rate over the same period last year. At the same time the first three quarters of traditional Chinese medicine companies operating revenue23.55%, operating profit grew by 33.27%, mayinglong, Yi-Bai pharmaceuticals, tasly, ConMed pharmaceuticals, Kunming pharmaceutical, pientzehuang and Dong-e e-Jiao, and other related good corporate earnings. Chinese herbal medicine and proprietary Chinese medicine both sub-sectors are growing faster, 2011-September proprietary Chinese medicines revenues $ 172.9 billion, an increase of 34.6%, totalling 17 billion yuan in profits, an increase of 28.4%. January-September of prepared traditional Chinese medicines industry revenues of $ 41.6 billion yuan, an increase of 53%, the profits, 31.7%, an increase of 56.4%. Herbal industry revenue, gross profit and gross margin per cent growth rate than traditional Chinese medicine industry, mainly by the price of Chinese medicinal materials in price, LeeRun due to redistribution in the industry. Injections from traditional Chinese medicine industry market expanded under the guidance of injections from traditional Chinese medicine refers to the theory of traditional Chinese medicine, the use of modern technology, extracted from natural medicines effective sterilization preparation of material made available for injection in vivo. Injections may generally be divided into solution injection, powder for injection, injection with suspension and emulsion for injection and so on. Traditional Chinese medicine injectionOn traditional Chinese medicine, is the original new forms.　　It has high bioavailability, quickly, without gastrointestinal absorption, nor hepatic first-pass effect, to overcome the effect of traditional Chinese medicine slowly enough, while both traditional Chinese medicine fuzheng quxie, clearing, the advantages of promoting blood circulation and removing blood stasis swtor power leveling, enhance the body immunity. Compound growth rate of 30% injections from traditional Chinese medicine market in recent years, higher than theAverage growth rate in medical industry. Statistics show that in nine cities in 2010 amount of proprietary Chinese medicines, injections formulations accounted for less than the maximum, over traditional forms such as capsules, tablets, around 35.47%. Injections from traditional Chinese medicine widely used in cardiac and cerebral vascular disease, tumor diseases, respiratory diseases, musculoskeletal system diseases and diseases of the digestive system of the five major disease areas,A good therapeutic effect.　　Cardio-cerebral-vascular areas account for less than the maximum, to 59.71%, while in the field of anti-tumor and the area of the respiratory system, injections from traditional Chinese medicine also has a star product. In 2011, Polyphenolic acids of Salvia miltiorrhiza injection of tasly company approved, this variety was the first since 2008 was granted a variety of injections from traditional Chinese medicine, this year is expected to be aboveCity for sale. Polyphenolic acids of Salvia miltiorrhiza injection approved, marking the traditional Chinese medicine injection approval Gates opened again, policy loosening is expected to bring rapid development to the industry of new opportunities. New forms of injections from traditional Chinese medicine is our original, is the exploration of the future international pharmaceutical industry marketing one of the unique advantages of the project, there is great market demand. On the international markets, particularly Germany and other European countries, Plant production and clinical use of drug injection technology also has been widely recognized. Derivatives derivatives icing on traditional Chinese medicine of traditional Chinese medicine is based on a traditional Chinese medicine, the use of specific attributes of traditional Chinese medicine, different appeal to consumers, healthy combination of elements and everyday life a group of products, covering all aspects of people's lives. Current product market potentialHuge, attract many enterprises, especially traditional medicine enterprises to join in and in just a few years time, the derivative market of traditional Chinese medicine have begun to take shape, today mainly concentrated in traditional Chinese medicine, Chinese medicine health products, and other fields. Daily chemical means of traditional Chinese medicine pharmaceutical enterprise based on the principle of traditional Chinese medicine, combining elements of traditional Chinese medicine and daily chemical products, pharmaceutical, health care, cosmetic products, when multiple properties.With the inflow of imported cosmetic, some domestic companies started looking for cosmetic development road with Chinese characteristics, some pharmaceutical companies involved in skin care products market, such as tongrentang, pientzehuang enterprises entering the health care market segments of traditional Chinese medicine the old republic power leveling, launched a series of skin care products. As the disposable income of urban residents and growing spending power, more daily chemical industry, pharmaceutical enterprises across territories and strong themes of traditional Chinese medicine of fineMarket, themes of traditional Chinese medicine product market share increase year by year, showing the tremendous potential of the domestic market.　　According to the first half of 2010, Yunnan baiyao toothpaste market share amounted to 10%, become a national brand of toothpaste. At present the Ministry of health health food is 22 kinds of admissibility, including the regulation of immune and regulating blood lipid, regulation of blood sugar, such as regulating blood pressure, anti-aging。 In addition, there is resistance to oxidation, improve microcirculation, block the synthesis of n-nitroso compounds, increased white blood cell and caries in teeth, beauty in the abundance of milk. One such blood products of traditional Chinese medicine has always been the choice for consumers, Dong-e e-Jiao products are consumers of the product. Pientzehuang is China's top secret prescription drugs, but because natural musk pientzehuang recipes belong toResource depletion of raw materials, product is in short supply.　　By 2012 the health food market in China will reach $ 120 billion in sales, the tremendous potential of the market is expected to become channels for enterprises to speed up the growth of traditional medicine. Securities code name securities circulation equity net assets per share third quarter earnings per share stocks highlights 600,436 pientzehuang 1.48.05 1.381 high-end consumer demand, into the cosmetic and health products market 600,535 tasly 4.88 6.81 benefited from primary health care marketing and application development, Dan-Shen root dropping pill in the pace of Yunnan baiyao 6.29 7.5 baiyao 000538 product growthStable, the two wings of products focused on commodity market of traditional Chinese medicine 000423 Dong-e e-Jiao 6.54 deep blood market, diversification strategies prompted value regression 300,026 Sun pharmaceuticals 0.54 6.13 both antithrombotic drugs production and marketing, North market monopoly